S2N.Bio commences technology transfer of Alzheimer’s cell therapy to Cell Therapies’ Melbourne GMP facility
Cell Therapies Pty Ltd and S2N.Bio (“S2N”) have commenced technology transfer of S2N’s cell therapy candidate for Alzheimer’s disease. The transfer will enable GMP manufacture of clinical trial material for S2N’s first-in-human study in Australia.
Read original article on The Medical News →Related news
-
Caregivers with heart disease face high psychological distress risks
United Kingdom
-
Why teaching AI about symmetry could make prenatal diagnosis more reliable
United Kingdom
-
Hormone therapy use associated with greater migraine burden in postmenopausal women
United Kingdom
-
Anxiety and depression linked to higher levels of pregnancy "brain fog"
United Kingdom
-
Preschool social-emotional lessons improve long-term adult well-being
United Kingdom
-
Scientists finally uncover why statins can cause muscle pain
United States
-
Texas Man Finds More Than $128,000 on Top of a Bank’s ATM–and Returns Every Dollar
United Kingdom
-
Potential tissue effects: Microablative fractional radiofrequency in postmenopausal women
United Kingdom